| pubmed-article:10534733 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10534733 | lifeskim:mentions | umls-concept:C0019351 | lld:lifeskim |
| pubmed-article:10534733 | lifeskim:mentions | umls-concept:C0017968 | lld:lifeskim |
| pubmed-article:10534733 | lifeskim:mentions | umls-concept:C0086231 | lld:lifeskim |
| pubmed-article:10534733 | lifeskim:mentions | umls-concept:C0020980 | lld:lifeskim |
| pubmed-article:10534733 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:10534733 | lifeskim:mentions | umls-concept:C0600367 | lld:lifeskim |
| pubmed-article:10534733 | lifeskim:mentions | umls-concept:C1881488 | lld:lifeskim |
| pubmed-article:10534733 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10534733 | pubmed:dateCreated | 2000-1-12 | lld:pubmed |
| pubmed-article:10534733 | pubmed:abstractText | Seroepidemiology studies of herpes simplex virus type 2 (HSV-2) infections have been difficult to carry out because antibodies to HSV type 1 (HSV-1) show an extensive cross-reactivity with HSV-2 antigens. Many kits available currently are not entirely type specific for serodiagnosis of HSV-2 infections and therefore do not allow reliable discrimination of past exposure to these closely related alphaherpes viruses. Attempts to develop type-specific antigens have focused on the envelope glycoproteins, particularly glycoprotein G (gG). A cross-sectional study was carried out to examine the seroprevalence of antibodies to HSV-2 among healthy university students, using different methods: a whole cell lysate enzyme-linked immunosorbent assay (ELISA), two different ELISAs, and a newly developed immunoblot assay, the last three based on recombinant gG2. HSV-2 prevalence was 24 times higher with the whole cell lysate ELISA (31%; 95% confidence interval [CI]: 27-35%) than the ELISAs and the immunoblot assay based on recombinant gG2 (1.3%; 95% CI: 0.1-2.5%), thus showing the inaccuracy of commercial tests based on whole-antigen preparations for epidemiological studies. Laboratories should be cautious and ensure that commercial tests for HSV typing are based on type-specific glycoproteins. | lld:pubmed |
| pubmed-article:10534733 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10534733 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10534733 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10534733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10534733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10534733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10534733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10534733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10534733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10534733 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10534733 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:10534733 | pubmed:issn | 0146-6615 | lld:pubmed |
| pubmed-article:10534733 | pubmed:author | pubmed-author:GilAA | lld:pubmed |
| pubmed-article:10534733 | pubmed:author | pubmed-author:AguilarLL | lld:pubmed |
| pubmed-article:10534733 | pubmed:author | pubmed-author:BayasJ MJM | lld:pubmed |
| pubmed-article:10534733 | pubmed:author | pubmed-author:Dal-RéRR | lld:pubmed |
| pubmed-article:10534733 | pubmed:author | pubmed-author:García-Corbei... | lld:pubmed |
| pubmed-article:10534733 | pubmed:author | pubmed-author:VilellaAA | lld:pubmed |
| pubmed-article:10534733 | pubmed:author | pubmed-author:García-de-Lom... | lld:pubmed |
| pubmed-article:10534733 | pubmed:author | pubmed-author:HogrefeWW | lld:pubmed |
| pubmed-article:10534733 | pubmed:copyrightInfo | Copyright 1999 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:10534733 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10534733 | pubmed:volume | 59 | lld:pubmed |
| pubmed-article:10534733 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10534733 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10534733 | pubmed:pagination | 502-6 | lld:pubmed |
| pubmed-article:10534733 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:meshHeading | pubmed-meshheading:10534733... | lld:pubmed |
| pubmed-article:10534733 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10534733 | pubmed:articleTitle | Whole cell lysate enzyme immunoassays vs. recombinant glycoprotein G2-based immunoassays for HSV-2 seroprevalence studies. | lld:pubmed |
| pubmed-article:10534733 | pubmed:affiliation | Medical Department, SmithKline Beecham Pharmaceuticals, Madrid, Spain. | lld:pubmed |
| pubmed-article:10534733 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10534733 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10534733 | lld:pubmed |
